Articles On Imugene (ASX:IMU)

The S&P/ASX 200 Index (ASX: XJO) finished the week in the green, gaining 0.48% on Friday to close at 7,145.1 points. That sees it having fallen 0.14% over the course of this week. It comes as the market gears up to hear the Reserve Ban...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

ASX 200 lithium shares fell against the benchmark S&P/ASX 200 Index (ASX: XJO) today. Lithium explorers that finished in the red included: Pilbara Minerals Ltd (ASX: PLS) down 1.59% Allkem Ltd (ASX: AKE) down 3.64% Core Lithi...

The ASX 200 finished the day higher, up 0.2 per cent at 7,110.8 points, after the United States’ house of representatives passed a bill to suspend the $31.4 trillion debt ceiling until 2025. Asian markets also fared well, with the Nikkei...

A new month is here, so what better time to look at some new additions to your portfolio? If you’re on the lookout for some ASX 200 stocks to buy, then it could be worth listening to what Goldman Sachs is saying this week. Buy this ASX 2...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.35% to 7,116.3 points. Four ASX shares that have failed to follow the market higher today ar...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

Highlights IMU, an Australian immuno-oncology company, has dosed first patient in the combination cohort of IMPRINTER study Imugene’s study assesses safety, efficacy, and optimal dose of PD1-Vaxx combined with atezolizumab in NSCLC pat...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) will collaborate with global biopharmaceutical company Roche on an Imprinter trial to evaluate the safety and...

Imugene (ASX:IMU) has announced that the first patient has been dosed in the combination cohort of the IMPRINTER trial.

After starting the day off on the wrong foot, the S&P/ASX 200 Index (ASX: XJO) tumbled even further this afternoon to close the day 1.48% lower at 7,102.8 points. The apparent driver of its tumble was the latest Aussie inflation figur...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

ASX rare earths share Arafura Rare Earths Ltd (ASX: ARU) has plummeted in the last three months. The company’s share price has fallen 43% from 60 cents at market close on 24 February to the current share price of 36 cents. Arafura shares...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The S&P/ASX 200 Index (ASX: XJO) ended the week in the green, gaining 0.59% on Friday to close at 7,279.5 points. That leaves it 0.31% higher than it was this time last week. Leading the way was the S&P/ASX 200 Information Technolo...

For the final day of the trading week, the ASX was up more than 0.5 per cent. Ship building company, Austal (ASB), has leapt more than 25 per cent to crack the $2 dollar mark. It came off the back of news its US subsidiary won a $3 bi...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Cancer immunotherapy house Imugene (ASX: IMU) has received US Food and Drug Administration (FDA) approval to start a human trial targeting advanced or metastatic solid...

Immutep gets US FDA clearance to start Phase 1 study Noxopharm says its Sofra platform is effective against inflammatory skin disease Epsilon Healthcare announced a new CEO   US FDA approves Imugene’s Phase 1 Immuno-oncology biotech Imug...

Imugene (IMU) receives US Food and Drug Administration (FDA) Investigational New Drug (IND) clearance to begin a study of its oncolytic virotherapy candidate, onCARlytics Through this clearance, IMU can start patient recruitment and dosi...

The ASX is expected to open slightly higher on Friday as reports suggest the US debt ceiling talks could be resolved within the coming days. It comes off the back of President Biden reassuring Americans yesterday the country would “not...

Highlights Combination of IMU’s onCARlytics and Eureka Therapeutics' ARTEMIS® cell receptor platform shows anti-tumour activity, says the company Hepatocellular carcinoma can occur in people affected by chronic liver diseases (cirrhosi...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has presented pre-clinical data at the American Society of Gene and Cell Therapy’s annual meeting to demonstr...

The S&P/ASX 200 Index (ASX: XJO) shook off early losses on Friday to close the final session of the week 0.07% higher at 7,256.7 points. That sees the index 0.51% higher week-on-week, thanks mainly to Monday’s 0.78% gain. The S&...

S&P/ASX 200 Index (ASX: XJO) lithium share Pilbara Minerals Ltd (ASX: PLS) is rocketing amid news peer Allkem Ltd (ASX: AKE) is to merge with Livent Corp (NYSE: LTHM), creating a $15.7 billion monolith. Right now, stock in Pilbara Min...

Engineering companies are not often discussed among ASX investors, but there are a couple at the moment that look like excellent buys. That’s according to Shaw and Partners portfolio manager James Gerrish, who said in his Market Matters ne...

Even though lithium prices have cooled off over recent months, battery ingredients such as that and rare earths will remain in high demand in the long run. This is especially because of one modern phenomenon. “Lithium-ion batteries are not...

The S&P/ASX 200 Index (ASX: XJO) slipped into the red on Tuesday, closing today’s session 0.17% lower at 7,264.1 points. Weighing on the market was the S&P/ASX 200 Real Estate Index (ASX: XRE). It slumped 1.4% today. It was also...

Ah, Budget Day. It’s pretty much Christmas for those of us who are both finance and politics nerds (you can send my wife your pity). I’ve written before about why I enjoy it so much and value it so highly, but it boils down to two thin...

The S&P/ASX 200 Index (ASX: XJO) seems to have taken a turn for the worse today. After yesterday’s positive start to the trading week, the ASX 200 has retreated so far this session. At the time of writing, the index has gone backwards...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday. In afternoon trade, the benchmark index is down 0.2% to 7,262.3 points. Four ASX shares that are not letting that hold them back today are listed below. Here’...

S&P/ASX 200 (ASX: XJO) stocks are down 0.3% at lunchtime on Tuesday, but as always, there are outliers. Today, ASX healthcare stock Imugene Limited (ASX: IMU) is leading the ASX 200 with its share price up 6% to 12 cents. The immunoâ...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Imugene (ASX: IMU) has unveiled “impressive” pre-clinical in vivo anti-tumour responses using its onCARlytics technology in combination with Eureka Therapeutics’ Arte...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The Imugene Limited (ASX: IMU) share price lifted 4% today after the company released its March quarter report. Imugene shares gained half a cent and were swapping hands at 13 cents in earlier trade but have since returned to their closing...

Today marked the penultimate day of March quarterly reports, and it appears to have pushed the materials sector up by half a per cent. Golden State Mining (GSM) was one of the many companies to release its results, and the market reacted...

Imugene’s (IMU) spent the March quarter continuing the development of its cancer-killing virus, VAXINIA IMU recently dosed the first patients in a combination and monotherapy trial of the drug after receiving ethics approval early in the...

Amid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught the eye of investors after some promising clinical news. These companies are working on so-called CAR-T therapies, which work by ‘superchar...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Imugene is developing immune-oncology to treat a range of cancers. Imugene (ASX: IMU) has more cash in the bank to pursue ongoing development of its immuno-oncology t...

Highlights Imugene has received its R&D tax refund of nearly AU$12.6 million for FY22. The Australian Government has provided the tax refund to IMU as part of its R&D tax incentive. IMU will use the refund amount to take forwa...

Imugene (IMU) presents positive imaging data from its viral drug oncolytic virotherapy candidate, CHECKvacc (CF33-hNIS-antiPDL1) SPECT data reveals potential local viral replication post-injection with resulting hNIS (human sodium iodide...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Clinical stage immune-oncology company Imugene (ASX: IMU) has revealed what it describes as positive imaging data on its oncolytic virotherapy candidate CHECKvacc in...

Highlights Imugene has presented positive imaging data on its oncolytic virotherapy candidate, CHECKvacc (CF33-hNIS-antiPDL1) at the AACR Annual Meeting 2023 in Orlando, Florida. The data was presented by Dr Jamie Rand, an Assistant Pr...

Local share will open flattish, tracking movements in New York Tesla’s profit margins plunge after aggressive cost cutting The RBA could be stripped of its interest rates setting powers   The ASX is poised to open flattish again on Thursd...

This ASX rare earths stock is exploding on the market today amid new drilling results. Larvotto Resources Ltd (ASX: LRV) shares soared 107% from 13.5 to 28 cents today before slightly retreating. The company’s share price is still up 85%...

When it comes to ASX lithium stocks, Nova Minerals Ltd (ASX: NVA) is probably not a share that initially comes to mind. But Nova Minerals is a $74 million company that has been listed on the ASX for more than two decades. It is primarily a...

Most index exchange-traded funds (ETFs) on the ASX work in a similar way. The fund tracks a single index, perhaps the S&P/ASX 200 Index (ASX: XJO), and by doing so, holds every share that the index tracks in the correct proportion. But...

The Imugene Ltd (ASX: IMU) share price has been racing ahead in the last month. Shares in the ASX 200 healthcare stock have risen 14.6% since market close on 17 March and are currently fetching 13.75 cents a share. For perspective, the S&...

The S&P/ASX 200 Index (ASX: XJO) spent the day in the green on Monday, rising 0.27% to close at 7,381.5 points. That was despite a disappointing Friday session on Wall Street. The Dow Jones Industrial Average Index (DJX: .DJI) ended l...

After wobbling in and out of the green this morning, the S&P/ASX 200 Index (ASX: XJO) cemented its position in the red on Thursday, closing the session 0.27% lower at 7,324.1 points. It followed a weak session on Wall Street overnight....

The S&P/ASX 200 Index (ASX: XJO) traded in the red ahead of the Easter long weekend, falling 0.25% to close Thursday’s session at 7,219 points. That left it 0.57% higher week-on-week. Weighing heaviest was the S&P/ASX 200 Inform...